Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4375-4380

  Abed, Yacine ^a   Pizzorno, Andrés ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENE MUTATION; IN VITRO STUDY; INFLUENZA A (H1N1); LOW DRUG DOSE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; FEMALE; GUANIDINES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; TREATMENT OUTCOME; VIRAL PROTEINS;

EID: 84864378886     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00753-12     Document Type: Article

References (35)

1. Abed Y, Boivin G. 2006. Treatment of respiratory virus infections. Antiviral Res. 70:1-16. (Pubitemid 43675656)
2. Abed Y, Goyette N, Boivin G. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9:577-581. (Pubitemid 39150215)
3. Abed Y, Nehme B, Baz M, Boivin G. 2008. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res. 77:163-166.
4. Abed Y, Simon P, Boivin G. 2010. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob. Agents Chemother. 54:2819-2822.
5. Arya V, Carter WW, Robertson SM. 2010. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. Clin. Pharmacol. Ther. 88:587-589.
6. Babu YS, et al. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43:3482-3486.
7. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. 2006. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 69:39-45. (Pubitemid 41790480)
8. Barroso L, Treanor J, Gubareva L, Hayden FG. 2005. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir. Ther. 10:901-910. (Pubitemid 43076341)
9. Baz M, Abed Y, Boivin G. 2007. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 74:159-162. (Pubitemid 46436166)
10. Birnkrant D, Cox E. 2009. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361:2204-2207.
11. Boivin G, Goyette N. 2002. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 54:143-147. (Pubitemid 34327680)
12. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
13. CDC. 2009. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:969-972.
14. CDC. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:433-435.
15. Cheung CL, et al. 2006. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193:1626 -1629.
16. de Jong MD, et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
17. Fiore AE, et al. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8):1- 62.
18. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45:2723-2732. (Pubitemid 32906663)
19. Gubareva LV, Webster RG, Hayden FG. 2001. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45:3403-3408. (Pubitemid 33107853)
20. Harper SA, et al. 2009. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1003-1032.
21. Hurt AC, et al. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90 -93.
22. Hurt AC, Holien JK, Barr IG. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:4433- 4440.
23. Meijer A, et al. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
24. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. 2010. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin. Infect. Dis. 50:1252-1255.
25. Mineno T, Miller MJ. 2003. Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents. J. Org. Chem. 68:6591-6596. (Pubitemid 37010963)
26. Mishin VP, Hayden FG, Signorelli KL, Gubareva LV. 2006. Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection. Antiviral Res. 71:64-68.
27. Moscona A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373. (Pubitemid 41362704)
28. Okomo-Adhiambo M, et al. 2010. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2:2269-2289.
29. Pizzorno A, Abed Y, Boivin G. 2011. Influenza drug resistance. Semin. Respir. Crit. Care Med. 32:409-422.
30. Pizzorno A, et al. 2012. Impact of mutations at residue i223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob. Agents Chemother. 56:1208-1214.
31. Pizzorno A, Bouhy X, Abed Y, Boivin G. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203:25-31.
32. Shetty AK, Peek LA. 2012. Peramivir for the treatment of influenza. Expert Rev. Anti Infect. Ther. 10:123-143.
33. Ward P, Small I, Smith J, Suter P, Dutkowski R. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. 1):i5-i21. (Pubitemid 40331165)
34. Wright PF, Webster RG. 2001. Orthomyxoviruses, p 1533-1562. In Knipe DM, et al (ed), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
35. Yun NE, et al. 2008. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374:198-209.